COMPANY

Actinium Pharmaceuticals, Inc.

Keywords: oncology acute myeloid leukemia Acute Myelogenous Leukemia Relapsed Adult AML AML Acute Leukemia Myelogenous Leukemia Myelogenous Leukemia in Relapse Transplant-Related Disorder Allogeneic Disease Refractory AML Leukemia, Myeloid, Acute Bone Marrow Transplant Refractory Multiple Myeloma Lintuzumab AC 225

Profile checked Oct 10, 2026

6Trials (company is sponsor)3NIH grants

Timeline

2026-01 Trial start Phase 2/Phase 3: Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML source ↗
2023-03 Trial start Phase 1/Phase 2: Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients source ↗
Jan 15, 2020 Trial start Phase 1/Phase 2: Venetoclax and Lintuzumab-Ac225 in AML Patients source ↗
2016-12 Trial start I: A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma source ↗
2016-06 Trial start Phase 3: Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia source ↗
2012-10 Trial start Phase 1/Phase 2: Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients source ↗

Upcoming milestones

2029-02 (ESTIMATED) · Phase 2/Phase 3 · Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML · NCT07157514

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT07157514	Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML	Phase 2/Phase 3	Not yet recruiting	2026-01	2029-02 (estimated)
NCT03867682	Venetoclax and Lintuzumab-Ac225 in AML Patients	Phase 1/Phase 2	Unknown status (ClinicalTrials.gov)	Jan 15, 2020	2023-11 (estimated)
NCT03932318	Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients	Phase 1/Phase 2	Withdrawn	2023-03	2023-12 (estimated)
NCT02575963	Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients	Phase 1/Phase 2	Completed	2012-10	2018-11 (actual)
NCT02665065	Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia	Phase 3	Active, not recruiting	2016-06	2022-06 (actual)
NCT02998047	A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma	I	Terminated	2016-12	2020-05 (actual)

NIH awards 3

Annual award amounts. Total $2.1M.

Sep 11, 2024 NIH award 5R42CA254685-03 FY2024: $865,308 awarded for that fiscal year; activity R42 (STTR); PI DESAI, AVINASH; recipient as written: ACTINIUM PHARMACEUTICALS, INC., New York, NY. Iomab-ACT: A phase I/II study of 13 source ↗
Jul 24, 2023 NIH award 4R42CA254685-02 FY2023: $865,308 awarded for that fiscal year; activity R42 (STTR); PI DESAI, AVINASH; recipient as written: ACTINIUM PHARMACEUTICALS, INC., New York, NY. Iomab-ACT: A phase I/II study of 13 source ↗
Sep 9, 2020 NIH award 1R42CA254685-01 FY2020: $378,389 awarded for that fiscal year; activity R42 (STTR); PI BERGER, MARK S; recipient as written: ACTINIUM PHARMACEUTICALS, INC., New York, NY. Iomab-ACT: A phase I/II study of 13 source ↗